Govt intends to lower the prices of critical drugs on August 15
The Centre may announce a vital decision on August 15 to dramatically lower costs of several essential drugs, such as those for cancer, diabetes, and cardiovascular diseases, in a move that is anticipated to relieve many patients by lowering the expense of healthcare.
Pharma sales increase in June following two month decline
After tumbling into negative territory over the previous two months, the domestic pharma retail industry may be beginning to show signs of life soon. The recovery was fueled by outstanding results in both chronic and acute therapies, as well as new drug launches.
Anti-narcotics agencies increase vigilance against drug diversion in Himachal's pharma hub
Anti-narcotics agencies have increased their vigilance in North India following recent cases of pharmaceutical units expanding into the production of synthetic drugs, in Asia’s largest bulk drug manufacturing hub of Baddi and Batoriwala in Himachal Pradesh.
Sun Pharma & Glenmark recalling products in US owing to production concerns
According to USFDA’s most recent enforcement report, a US-based Sun Pharma division is recalling 50,680 vials of Testosterone Cypionate Injection, which is used to treat low testosterone in adult males.
Eli Lilly & Triastek collaborate for 3D Print gastrointestinal drug
Triastek, a Chinese medication 3D printing business, has announced a collaboration with Eli Lilly, a worldwide pharmaceutical company, to investigate and manufacture 3D printed oral drugs for the gastrointestinal tract.
EMA's Human Medicines Committee advises restricting the use of cancer drug Rubraca
Rubraca (rucaparib camsylate) should no longer be used as a third-line treatment for ovarian, fallopian tube, or peritoneal cancers with a BRCA mutation in patients, as per the European Medicines Agency’s (EMA) human medicines committee
Bangladesh: Pharma needs to get ready for post-LDC era
Bangladesh should immediately begin
researching how to capitalize on its potential to
make billions from the global pharma market
as the nation will lose its favorable trade perks
in 2026 when it no longer qualifies as an LDC
(Least developed Country).
